Highly active disease and access to disease-modifying treatments in patients with relapsing-remitting multiple sclerosis in Poland | Zendy

Waldemar Brola | Zendy; Monika AdamczykSowa | Zendy; Alina Kułakowska | Zendy; Joanna Głażewska | Zendy; Anna Smaga | Zendy; Halina Bartosik-Psujek | Zendy

Open Access

Highly active disease and access to disease-modifying treatments in patients with relapsing-remitting multiple sclerosis in Poland

Author(s) -

Waldemar Brola,

Monika AdamczykSowa,

Alina Kułakowska,

Joanna Głażewska,

Anna Smaga,

Halina Bartosik-Psujek

Publication year - 2022

Publication title -

neurologia i neurochirurgia polska

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.484

H-Index - 26

eISSN - 1897-4260

pISSN - 0028-3843

DOI - 10.5603/pjnns.a2022.0047

Subject(s) - medicine , reimbursement , second line , disease , relapsing remitting , multiple sclerosis , retrospective cohort study , pediatrics , first line , psychiatry , health care , economics , economic growth

In Poland, access to second-line disease-modifying treatments (DMTs) for relapsing-remitting multiple sclerosis is limited by reimbursement criteria that require evidence of more aggressive disease compared to the approved indications.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research